Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01223937 · ClinicalTrials.gov registry record · Phase 3
Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
NCT01223937 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 268 participants.
The verdict
NCT01223937, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
Study Summary
A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with nocturia.
Interventions
- DRUG Placebo
- DRUG Desmopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01223937
The ClinicalTrials.gov registry entry for NCT01223937 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01223937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01223937 about?
NCT01223937 is a clinical study titled "Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients". A multicenter, randomized, double-blind, placebo-controlled, parallel-group trial to investigate the safety and efficacy of desmopressin oral melt tablets against placebo during 3 months of treatment in adult females with nocturia.
What is the current status of trial NCT01223937?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 2010-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01223937?
The interventions under investigation include: Placebo (DRUG), Desmopressin (DRUG).
Who is sponsoring clinical trial NCT01223937?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.